Recent Advances of Integrative Bio-Omics Technologies to Improve Type 1 Diabetes (T1D) Care
Round 1
Reviewer 1 Report
Dear authors
Manuscript is well organized, written and addressing relevant topics under the major topic of Type 1 Diabetes, although in a very generalist way, not going deep enough in several chapters of the manuscript. The connection between the chapters is also weak. Must be improved.
Trough all paper to be changed:
Authors name should not be in italic, only the et al., that must have a dot at the end. Lines: 85, 96, 103, 117, 125, 137, 177, 190, 199.
in vitro and in vivo as well as versus, must be written in italic once it is Latin, check all manuscript. Line 96.
Trough all paper first we write fully and only after the abbreviation, and once we have done from there on only use the abbreviation. Check all document. Examples lines :75, 86, 119, 120, 138.
Line 93 use only TEDDY, already abbreviated previously
All genes must be written in italic trough all manuscript. Lines 75, 80, 82, 86
Line 130 check how to write hypothurodism - hypothyroidism.
Abstract
Generalist and hardly reflect the manuscript, suggestion that the chapters addressed are reflected here, as well as the conclusions of the manuscript.
There is an abbreviation without being written fully previously S.T.EM.
There is no reference supporting the sentence from line 60 to 62.
All chapters must be deepen.
Prevention the authors addressed the immune system and the transcriptomic but without examples.
On chapter 3. Pathogenesis and Biomarkers, no biomarkers are clearly identified/presented and the interleukins presented, are not explained how the act. If the authors think some are relevant, they must be highlighted at discussion and conclusion.
Diagnostic methods besides the ones daily used Worldwide ( not mentioned) the other is not clear how relevant they are. Last sentence of this chapter lines 129 to 132 must describe how and the connection that may exist. And what common genetic variability exist?
Last sentence of chapter 8 complications of T1D, (lines 206 to 210) must be written in a more deepen way and clarifying how peripheral artery disease happens and the mechanisms involved.
Oxidative stress mentioned in lines 221 to 225 , must be clarified how it affects, namely the pollutants.
Discussion must be deepened. Last sentence must be improved and give possible examples based on the previous information written.
The manuscript misses the weak points of the manuscript
Author Response
Please see the attachment.
Author Response File: 
Author Response.docx
Reviewer 2 Report
The manuscript “Recent advances of Integrative Bio-Omics Technologies to Improve Type 1 Diabetes (T1D) Care” highlight the role of omics in prevention, pathogenesis, diagnostics, and treatments of T1D.
The manuscript is well written and addresses key issues like how biological data can be merged with personal and electronic health records to tailor medical interventions to the patient’s biology and lifestyle. However, there are some points that need to be addressed by the authors before considering this article for acceptance in the reputed journal for publication.
Minor comments:
In line no. 43 authors mentioned that genetic predispositions and environmental influences on T1D can not only be explored but may help identify at-risk individuals requiring early interventions but did not cite any reference. There is a recent article published in Diabetes journal by Peter Arvan group mentioned that “Predisposition to Proinsulin Mis-folding as a Genetic Risk to Diet-Induced Diabetes”. It would be better if authors mention this article in this review.
Also, I would recommend authors to add more about how Omics help in the study of drug-drug interaction to treat T1D.
Author Response
Please see the attachment.
Author Response File: Author Response.docx
Round 2
Reviewer 1 Report
Dear authors
The manuscript is fine for publication.
Keep safe.
